A TG Therapeutics multiple sclerosis drug that’s new to the U.S. market will be commercialized in Europe and other regions under a partnership that pays the
Current global financial conditions make it difficult for publicly traded biotech companies to raise money through conventional stock offerings, so some co
/cloudfront-us-east-2.images.arcpublishing.com/reuters/I3BYYDLGPNOORN5UMU6HPECDSA.jpg)